Diabetes, metformin and gastric adenocarcinoma
Abstract
Diabetes may increase the risk and mortality of certain cancers, but its association with gastric adenocarcinoma is not clear. On the other hand, metformin, a first-line treatment for diabetes, may reduce cancer risks and improve cancer-related survival, but these associations have not been confirmed in gastric adenocarcinoma as well. The aim of this thesis is to evaluate if and how diabetes or its biomarkers and the use of metformin influence the risk and prognosis of gastric adenocarcinoma. Study I investigated if diabetes or prediabetes influenced the risk of gastric adenocarcinoma in a population-based Swedish cohort. Participants of the Northern Swedish Health and Disease Study were included and followed up from 1985 to 2017. Participants exposed to diabetes or prediabetes, as confirmed by self-reports or oral glucose tolerance tests, were compared with those of normoglycaemia for the incidence of gastric adenocarcinoma, identified from the Swedish Cancer Registry. Cox proportional hazard regression analyses with adjustment for sex, age, calendar year, body mass index, tobacco smoking, and education level showed no associations between prediabetes or diabetes and the risk of gastric adenocarcinoma (hazard ratio [HR] 1.07, 95% confidence interval [CI] 0.79-1.44 for prediabetes; HR 0.77, 95% CI 0.46-1.29 for diabetes). Study II was a systematic review and meta-analysis assessing associations between serum Haemoglobin A1c (HbA1c) or glucose and the risk of developing…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.